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In keeping with the theme of this Yale-China symposium, we discuss some unexpected
dividends which have been derived from the basic study of five viruses to which man has been
exposed. Inquiring into the behavior of these viruses for their own sake has not only produced
an increase in basic understanding of biologic processes, but has provided concepts and
techniques which will broaden our knowledge of the etiology, pathogenesis, and treatment of
human diseases which are unrelated to viruses.
INTRODUCTION
In this paper we shall attempt to summarize some unexpected ways in which
human viruses have proven to be beneficial to their natural host-man. The concept
of"beneficial human viruses" represents a recent change in thethinking ofmicrobiol-
ogists about their subjects. From an initial preoccupation with microbes as etiologic
agents in infectious diseases, microbiologists are now focused on ways in which
microorganisms can instruct them in the nature of basic biologic processes and on
efforts to use microorganisms to produce interesting and potentially useful macro-
molecules.
Medical virology was initially the domain ofclinicians and researchers who wished
to prevent viral disease. The beneficial effects to man of their efforts cannot be
overstated. The isolation of the etiologic agents of smallpox, poliomyelitis, measles,
yellow fever, rubella, and mumps, and the preparation of effective, easily adminis-
tered vaccines against these classical epidemic viral diseases of man surely rank
among the great triumphs of public health. Nevertheless, definite challenges remain
in answering numerous perplexing questions. How exactly did these efforts, based
largely on the empirical efficacy of vaccination with attenuated live viruses, succeed
in conferring protection against later infection with the true viral pathogen? More-
over, what type and degree of protection was conferred to the vaccinated subject and
specifically how did the mediators of host resistance act? For despite the eradication
of smallpox from the world and the near total elimination of poliomyelitis from our
country, we still have only vague and untested ideas of how such avirulent live virus
vaccines work. More specifically, we do not know why wild-type poliomyelitis virus
occasionally affects certain cells in the nervous system or why attenuated vaccine
57
Based on a talk delivered by George Miller at the Yale China Symposium on Beneficial Effects of
Viruses in honor of Dr. Gao.
Parts ofthis paper were presented at the medical symposium sponsored by the Yale-China Association
on September 13, 1979. Convener: G.D. Hsiung
Address reprint requests to: George Miller, M.D., Department of Pediatrics, Yale University School of
Medicine, 333 Cedar St., New Haven, CT 06510
Copyright i 1981 by The Yale Journal of Biology and Medicine, Inc.
All rights of reproduction in any form reserved.MILLER AND FISCHER
virus almost always fails to do so. The irony is that these avirulent strains are
beneficial agents to man only because they are antigenically related to viruses which
are definitely harmful.
This lack of fundamental knowledge about the basic mechanisms involved in the
life cycle ofviruses has led to intense scrutiny ofthe biology and molecular biology of
all classes of human viruses. We will provide five examples oftheways in which such
study has provided new concepts and methods.
SV40-A MODEL FOR CANCER RESEARCH
Simian virus 40 was originally isolated as a contaminant from rhesus monkey
kidney cells used for the production of early batches of poliovirus vaccines [1]. The
natural hosts ofSV40 are monkey cells in which a permissive or productive infection
can proceed; however, when rodent or human cells which do not permit complete
replication of the virus are infected, a fraction of the exposed cells becomes
"transformed" into cells with properties of cancer cells.
The cell transformation phenomenon can be studied using the tools of molecular
genetics, since viral DNA persists in the altered cell and integrates into the host
genome. In the transformed cell only a portion of the integrated genome is
transcribed into mRNA. This mRNA is encoded bythe so-called "earlyregion" ofthe
genome. The gene products of this region are implicated in the transformation
process, for mutations in the early region lead to loss ofthe ability of SV40 to induce
or maintain the transformed phenotype [2].
The major gene products ofthe early region are two proteins, the tumor antigens,
called big T (94 K MW) and little t(19 K MW). ThelargeT antigen is known to have
several interesting properties. It is a DNA binding phosphoprotein, which binds
preferentially to the origin of DNA synthesis of the viral genome [3]. It stimulates
both viral and cellular DNA synthesis [4]. It is closely associated with host cell
proteins (host tumor antigens) which are present in a wide variety of human and
nonhuman tumors [5].
Thus SV40 has provided us with a number of useful phenomena which will
certainly clarify disease mechanisms. These include a reproducible way to change a
normal human cell into a malignant one, a method ofintegratingforeign DNA into a
normal chromosome, and the definition ofone or moreproteins which seem to affect
cellular DNA synthesis.
The hope is that unravelling the mechanisms of oncogenesis by asimplevirus such
as SV40, which contains only about 5,200 nucleotides, will provide insights which are
generally applicable to other carcinogenic agents. The most optimistic idea is that
various oncogenic agents, viral or otherwise, will follow a final common pathway.
ADENOVIRUSES-THE DISCOVERY OF RNA SPLICING
Adenoviruses are larger, more complex agents than SV40 for they contain about
20 x 106 Daltons of DNA (about seven times the amount in SV40). These viruses
cause a variety of different diseases of the respiratory tract of man, including
conjunctivitis, pharyngitis, and pneumonia [6]. They establish latent infections in the
lymphoid tissue (hence the name "adeno") of the nose and throat, and they can
readily be recovered from tonsils and adenoids [7]. The role that these persistent
viruses play in the genesis of disease has not been clarified.
Adenoviruses, like SV40, cause transformation of cultured rodent cells. All
serotypes of adenovirus are able to induce morphologic changes in tissue cultures,
but only some serotypes are oncogenic in animals. Thus adenoviruses have made
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clear that cell transformation studied in vitro and oncogenesis in the intact animal are
distinct processes [8].
Apart from their utility as models for studying cancer, adenoviruses have played a
major role in research on transcription of messenger RNA. In part, adenoviruses
were destined for such a role since they can be grown in very large quantities in the
laboratory in cell culture and because adenoviral infection ofhuman cells results in a
productive, lytic infection in which host cell DNA and RNA syntheses drop
dramatically. Since host RNA synthesis is inhibited, viral message can be isolated
and studied in relatively pure form. It was soon discovered by Darnell and his
collaborators that very large adenovirus 2 (Ad 2) RNA species were found in the cell
nucleus, but far smaller adenoviral mRNAs became associated with the cytoplasmic
ribosomes [9]. This led to the idea of processing ofthe mRNA in which large nuclear
RNA species are shortened in some fashion as they are being transported to the
cytoplasm. Philip Sharp and his colleagues subsequently noticed that Ad 2 mRNAs
contained sequences from sometimes widely separated regions of the genome [10].
The splicing process involves transcription of a large primary transcript with a
retained 5' leader sequence, the looping out and elimination of intervening non-
mRNA sequences, and the ligation of the 5' end with coding sequences downstream.
The coding regions of the gene are called exons and the eliminated regions removed
bythe splicing reaction, introns. Thus the transcript ofa gene may be much smaller in
size than the gene itself.
RNA splicing, initially discovered in adenovirus, has turned out to be a general
feature ofthetranscription ofmany, but not all, viral and cellular genes. Forexample
splicing has been demonstrated to occur in the synthesis of mRNAs coding for
hemoglobins and immunoglobulins [11,12]. Improved understanding of the thalas-
semias and of a variety of immune deficiency states will be achieved as the result of
the discovery of splicing.
HERPES SIMPLEX VIRUS-TECHNIQUES FOR GENE TRANSFER
Herpes simplex virus (HSV) causes a number of human diseases such as herpes
labialis, herpes genitalis, encephalitis, and disseminated neonatal infection [13]. The
virus remains latent in the sensory trigeminal or sacral ganglia and can be periodi-
cally reactivated. The herpes simplex genome is a very large and complex molecule
containing over 100 million daltons of DNA [14]. One of its genes specifies an
enzyme thymidine kinase (TK), which catalyzes the phosphorylation of pyrimidine
nucleotides. The TK enzyme is not essential for replication ofherpes simplex virus in
vitro but it appears to be needed for infection in vivo and for the establishment of
latency [15].
Normal cells also contain a TK enzyme, which is distinguishable from the viral
enzyme on the basis of several properties. Mutant cells which do not express the TK
enzyme can be isolated bygrowth in the presence ofbromodeoxyuridine (BrdU) [16].
Cells which become resistant to BrdU do not possess TK activitywhich is needed for
the phosphorylation of the drug and its incorporation into DNA where it exerts its
lethal effect. Selective media are also available in which cells lacking TK will not
grow [17].
Several years ago it was discovered that the herpes virus TK enzyme could be used
to convert cells which lacked a TK enzyme into ones which expressed it [18]. The
experiments were first done with inactivated virus and later with intact viral DNA
[19]. Recently transfer of the viral TK gene has been accomplished with a small
fragnent of herpes viral DNA which has been cloned on abacterial plasmid. During
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Wigler and his colleagues made a surprising finding. Cells which took up the herpes
DNA fragment and became stably transformed also took up other DNA molecules,
regardless of their specificity. Thus by using the TK selection system, it became
possible to transfer other eukaryotic genes [20]. Recently Ruddle and his colleagues
at Yale have transferred the HSV TK genes to mouse eggs by microinjection, and
they have raised mouse embryos which contain the herpes viral TK gene [21].
Viruses will increasingly be used to bring about gene transfer in human cells. It is
now possible to incorporate a gene which specifies globin into an SV40 DNA
molecule. Following infection of tissue culture cells with this recombinant DNA, the
cells make globin [22]. Gene transfer experiments are used to define the functions of
various regions of cellular and viral DNA and will ultimately be used as therapy for
genetic deficiencies.
PARAINFLUENZA VIRUS AND CELL FUSION
Parainfluenza virus, which causes croup in children, has proved to be a valuable
tool in development of genetics of eukaryotic cells. The Sendai strain of parainflu-
enza virus is highly potent in its ability to cause cells of different species to fuse and
form polykaryons (or polynucleate cells) and subsequently to become heterokaryons
and hybrid cells [23]. Fusion is brought about by a component of the Sendai virus
envelope. In mouse-human hybrid cells, human chromosomes are randomly lost and
mouse chromosomes selectively retained until the heterokaryon becomes stable. By
generating a large number ofclonal hybrid lines, each containing a different subset of
the human karyotype, and by comparing which proteins these hybrid lines express
with their chromosomal composition, an impressive number of genes have been
localized or mapped to specific human chromosomes [24]. Cell fusion mediated by
Sendai virus has given way to chemical cell fusion techniques, particularly by
polyethylene glycol, but this virus opened a whole new field of somatic cell
hybridization and its application in deciphering the genetics of eukaryotic cells.
Cell fusion also forms the basis of the so-called hybridoma method of producing
monoclonal antibodies [25]. This technique involves immunizing a mouse with a
partially purified or even complex antigen. The spleen cells are removed and fused
with a myeloma cell line, which provides signals for continuous cell growth in vitro
and possibly also for the secretion of large amounts of immunoglobulin. Selection is
applied against the myeloma line which has been made deficient in thymidine kinase
and thereby unable to grow in the HAT (hypoxanthine-aminopterin-thymidine)
selective medium. Therefore, only the hybrid spleen/ myeloma cells can grow. These
are diluted in microwells so that each microwell initially contains one cell, and is then
permitted to grow into mass culture. The fluid in each individual microwell is
screened for the presence of the desired antibody. Since each microwell was seeded
with one cell and according to immunologic theory one cell makes one antibody, the
secreted antibodies are "monoclonal."
Recently fusion hybrids between human lymphocytes and a human myeloma line
have been produced [26]. This should allow the production of human monoclonal
antibodies which will be useful in a great many areas of medicine. For example,
human monoclonal antibodies may be used to prevent specific diseases in situations
where immune globulins prepared from human serum are now used, such as
prophylaxis against chickenpox, hepatitis, or Rh-incompatible hemolytic disease.
Furthermore, human monoclonal antibodies will be useful in the study of a variety of
autoimmune diseases. It should be possible, for example, to make monoclonal
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antibodies which represent the spectrum
autoimmune responses of patients with
systemic lupus erythematosus.
THE EPSTEIN-BARR VIRUS AND LYMPHOID CELL LINES
Epstein-Barr virus, the etiologic agent of infectious mononucleosis, has the ability
to cause certain human lymphocytes to grow indefinitely in the laboratory under
tissue culture conditions, a process often referred to as immortalization [27]. The
target cell for EBV is a bone marrow-derived(B) lymphocyte[28]. The B lymphocyte
of any individual can be immortalized; without the addition of EBV, human
lymphocytes will remain alive for weeks to months, but they will not divide and will
eventually die off. The B lymphocyte immortalization capability of EBV has
numerous potential applications and benefits.
Lymphoblastoid cell lines remain more or less stable intheir chromosome number
and othergeneticcharacteristics, particularlyduring the first year oftheir in vitro life.
Thus EB virus can be used to establish cell lines from patients with a wide variety of
genetic disorders, such as abnormalities inhemoglobinsynthesis, in immunoglobulin
production, or disorders of DNA synthesis and DNA repair [29]. The biochemistry
of such defects can be analyzed in lymphoblastoid cells, much as they have been
analyzed in the past in skin fibroblasts from such patients. However, lymphoid cell
lines are easier to establish and grow more readily.
Lymphoblastoid cell lines express histocompatibility antigens on their surface; in
fact, the immortalized cells seem toexpress considerably more HLA antigens than do
fresh, or primary lymphocytes. Thus EBV provides the material for isolation,
purification, and biochemical characterization of different HLA antigens [30].
Certain lymphoblastoid lines secrete appreciable amounts of interferon into the
culture medium. There is a current renaissance of interest in the use of human
interferon as an antiviral agent; interferon also has cytolytic activity against certain
tumor cells. One pharmaceutical company has begun the commercial production of
interferon from large vats of a lymphoblastoid cell line called Namalwa [31].
Questions ofsafety of interferon produced by EB virus-transformed cells have been
raised; however, the other method of production of human interferon, namely
induction of interferon synthesis in different batches of fresh human leukocytes by
Sendai virus or Newcastle disease virus, also carries the risk of induction ofa variety
of different latent viruses from different leukocyte donors. Interferon purification has
progressed to the point where lymphoblastoid interferon would seem to be a safe
product. Interferon produced by bacteria containing recombinant DNA would now
seem to be the most likely source for clinical trials.
Recently Schlossman and colleagues at Harvard have put EBV to use in an
ingenious experiment. They were interested to know whether there were different
classes ofT, orthymus-derived lymphocytes in man, as have been described in mice.
They encountered a patient with an unusual form of chronic lymphocyte leukemia
derived from T cells. They reasoned that this T cell leukemia was monoclonal, i.e.,
derived fromjust onetype ofT cell. They raised an antiserum in a rabbit against the
leukemic cells. Then, to remove any activity which such an antiserum might have
against B lymphocyte surfaces, they established a B lymphocyte cell line from the
same patient by the use of EBV. The B lymphocyte line was then used to absorb the
antiserum, leaving a specific anti-T serum. Further experiments with this anti-T
serum showed that it reacted onlywith certaintypes ofTlymphocytes and not others.
Thus they had begun the subclassification and separation of human T cells into
helper and suppressor categories [32].
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B lymphocytes immortalized by EB virus are capable of immunoglobin (Ig)
synthesis. Our colleague Dr. Nathaniel Brown and others have shown that EBV
transformed cells can be cloned so that they produce only one type of heavy chain
and one type of light chain; that is, monoclonal immunoglobulin [33]. Some ofthese
clones secrete appreciable amounts of Ig into the culture fluid and in others the Ig
remains intracellular. The question now arises whether EBV can be used to establish
clonal B lymphocyte lines which are secreting a specific antibody. George Klein and
co-workers have made preliminary reports of human antibody made by lymphoblas-
toid cell lines obtained from lymphocytes of persons sensitized against a chemical
hapten [34]. Thus one possible future beneficial effect ofEBV might be in the in vitro
production ofhuman monoclonal antibodywithout the need forfusion to a myeloma
cell line.
These five examples of beneficial human viruses illustrate the way in which
practical benefits and basic research are inexorably intertwined. Many more benefi-
cial effects of viruses remain to be uncovered. However, these future benefits will
probably not come as the result of highly goal-oriented task forces or special
programs. Rather they are likely to be uncovered as small surprises which come
unanticipated during the course of basic research done for its own sake.
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